Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
27,421,678
-
Share change
-
+12,222,882
-
Total reported value
-
$556,952,380
-
Put/Call ratio
-
196%
-
Price per share
-
$20.32
-
Number of holders
-
80
-
Value change
-
+$249,098,444
-
Number of buys
-
57
-
Number of sells
-
16
Institutional Holders of TCR2 THERAPEUTICS INC - COM (TCRR) as of Q3 2020
As of 30 Sep 2020,
TCR2 THERAPEUTICS INC - COM (TCRR) was held by
80 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
27,421,678 shares.
The largest 10 holders included
MPM ASSET MANAGEMENT LLC, MPM ONCOLOGY IMPACT MANAGEMENT LP, Redmile Group, LLC, BlackRock Inc., WELLINGTON MANAGEMENT GROUP LLP, Consonance Capital Management LP, ArrowMark Colorado Holdings LLC, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), VANGUARD GROUP INC, and PFM Health Sciences, LP.
This page lists
80
institutional shareholders reporting positions in this security
for the Q3 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.